Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025

Rhea-AI Summary

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease treatments, will release its Q2 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. Investors can access the webcast through Liquidia's website, where it will remain archived for one year.

News Market Reaction – LQDA

+3.03%

+3.03% Session close to close

In the Aug 5 session, LQDA gained 3.03%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.

The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT^® Technology. PRINT enabled the creation of YUTREPIA™ (treprostinil) inhalation powder, a drug that has been approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

Contact Information

Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com

Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com

FAQ

When will Liquidia (NASDAQ: LQDA) report Q2 2025 earnings?

Liquidia will report its Q2 2025 financial results on Tuesday, August 12, 2025.

What time is Liquidia's Q2 2025 earnings call?

Liquidia will host its earnings webcast at 8:30 a.m. Eastern Time on August 12, 2025.

How can investors access Liquidia's Q2 2025 earnings call?

Investors can access the webcast through Liquidia's website at liquidia.com/investors/events-and-presentations. The recording will be archived for one year.

What does Liquidia Corporation (LQDA) do?

Liquidia is a biopharmaceutical company that develops innovative therapies for patients with rare cardiopulmonary disease.